Form 4: Ginkgo Bioworks Director Harry Sloan Reports Stock Transactions

Director Harry Sloan reports acquisition and vesting of restricted stock units and stock options in Ginkgo Bioworks Holdings, Inc.

Summary

• Harry Sloan, a director of Ginkgo Bioworks Holdings, Inc., reported transactions involving the company's Class A Common Stock.
• On June 12, 2024, 105,263 restricted stock units (RSUs) vested and converted into Class A shares.
• Following this transaction, Sloan directly owns 823,803 shares of Class A Common Stock.
• On June 13, 2024, Sloan was granted 432,900 additional RSUs and stock options for 571,428 shares.
• The stock options have an exercise price of $0.462 and expire on June 13, 2034.
• The vesting date for the new RSUs and the exercisable date for the stock options will be the earlier of June 13, 2025, or the day before the next annual shareholder meeting, contingent on continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transactions reflect standard compensation practices and alignment of the director's interests with the company's performance. There are no indications of negative sentiment.

Positives

• The vesting of RSUs and grant of new equity awards to a director signals continued alignment of interests between management and shareholders.
• The director's continued service is tied to the vesting of the new RSUs and stock options.

Future Outlook

The vesting of the new RSUs and the exercisability of the stock options are contingent upon the director's continued service with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment with company performance.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding director ownership.
• The equity grants incentivize the director to contribute to the company's long-term success.

Key Dates